162 related articles for article (PubMed ID: 34597305)
21. Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma.
Xu W; Rao Q; An Y; Li M; Zhang Z
PLoS One; 2018; 13(8):e0202763. PubMed ID: 30138346
[TBL] [Abstract][Full Text] [Related]
22. Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue.
Ning M; Duarte JD; Stevison F; Isoherranen N; Rubin LH; Jeong H
Clin Transl Sci; 2019 Jul; 12(4):416-423. PubMed ID: 30821899
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
[TBL] [Abstract][Full Text] [Related]
24. Four long noncoding RNAs as potential prognostic biomarkers for hepatocellular carcinoma.
Wang J; Pu J; Yao T; Lu X; Deng Y
J Cell Physiol; 2019 Jun; 234(6):8709-8716. PubMed ID: 30417366
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
26. Weighted correlation gene network analysis reveals a new stemness index-related survival model for prognostic prediction in hepatocellular carcinoma.
Zhang Q; Wang J; Liu M; Zhu Q; Li Q; Xie C; Han C; Wang Y; Gao M; Liu J
Aging (Albany NY); 2020 Jul; 12(13):13502-13517. PubMed ID: 32644941
[TBL] [Abstract][Full Text] [Related]
27. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
28. Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker.
Li C; Zhou D; Jiang X; Liu M; Tang H; Mei Z
Gene; 2019 May; 698():9-18. PubMed ID: 30825595
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implications of aberrantly expressed methylation‑driven genes in hepatocellular carcinoma: A study based on The Cancer Genome Atlas.
Li J; Chen N; Gong X
Mol Med Rep; 2019 Dec; 20(6):5304-5314. PubMed ID: 31661127
[TBL] [Abstract][Full Text] [Related]
30. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
31. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
32. Prediction and analysis of weighted genes in hepatocellular carcinoma using bioinformatics analysis.
Zhang Q; Sun S; Zhu C; Zheng Y; Cai Q; Liang X; Xie H; Zhou J
Mol Med Rep; 2019 Apr; 19(4):2479-2488. PubMed ID: 30720105
[TBL] [Abstract][Full Text] [Related]
33. Identification of prognostic biomarkers for patients with hepatocellular carcinoma after hepatectomy.
Wang X; Liao X; Yang C; Huang K; Yu T; Yu L; Han C; Zhu G; Zeng X; Liu Z; Zhou X; Qin W; Su H; Ye X; Peng T
Oncol Rep; 2019 Mar; 41(3):1586-1602. PubMed ID: 30628708
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
[TBL] [Abstract][Full Text] [Related]
35. Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.
Li Y; Qi D; Zhu B; Ye X
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540684
[TBL] [Abstract][Full Text] [Related]
36. Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report.
Lü Y; Zhang J; Li L; Li S; Yang Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 31990034
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
38. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ
Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
[TBL] [Abstract][Full Text] [Related]
40. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
